Evidence map›Paper›PMID 41298701›Full record

ArticleScientific reports2025

The recombinant protein of scorpion venom phospholipase A2 exhibits potential anti-leishmanial activity.

Parisa Soltan-Alinejad, Amin Ramezani, Qasem Asgari, Hamzeh Alipour, Aboozar Soltani, Mohammad Saleh Bahreini, Mahmood Nikbakhtzadeh, Kourosh Azizi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Parisa Soltan-AlinejadArthropod-Borne Diseases Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Amin RamezaniShiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Science, Shiraz, Iran.
Qasem AsgariDepartment of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Hamzeh AlipourResearch Center for Health Sciences, Department of Vector Biology and Control of Disease , Institute of Health, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Aboozar SoltaniResearch Center for Health Sciences, Department of Vector Biology and Control of Disease , Institute of Health, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Saleh BahreiniDepartment of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Mahmood NikbakhtzadehDepartment of Health Sciences and Human Ecology, California State University, San Bernardino, California, USA.
Kourosh AziziResearch Center for Health Sciences, Department of Vector Biology and Control of Disease , Institute of Health, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran. azizik@sums.ac.ir.

Funding

Shiraz University of Medical Sciences 98-01-04-20786.
6 · The paper itself

Abstract

The venom of scorpions contains a diverse array of bioactive compounds, including mucoproteins, nucleotides, and enzymes. Among these, phospholipase A

Indexed as

Antiprotozoal AgentsLeishmania majorPhospholipases A2Recombinant ProteinsScorpion VenomsAnimalsEscherichia coliMacrophagesMiceRAW 264.7 CellsScorpionsAntiprotozoal AgentsPhospholipases A2Recombinant ProteinsScorpion VenomsAnti-leishmaniaLeishmania majorPLA2Scorpio maurusScorpion

Identifiers

PMID41298701
PMCPMC12748955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.